{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T20:22:15Z","timestamp":1750537335527},"reference-count":13,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Nucl Med"],"published-print":{"date-parts":[[2020,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>The pelvis is a rare site for the origin of soft tissue sarcomas, and leiomyosarcoma remains the most common soft tissue sarcoma arising in the pelvis. Pelvic leiomyosarcomas are frequently aggressive tumors, and metastatic recurrence rates are high, with the lung, peritoneum, bone, and liver being the most frequent sites. We describe the findings of serial <jats:sup>18<\/jats:sup>F-FDG PET\/CT in a 53-year-old woman having pelvic leiomyosarcoma with uncommon site of metastasis, emphasizing the role of <jats:sup>18<\/jats:sup>F-FDG PET\/CT in response assessment.<\/jats:p>","DOI":"10.1097\/rlu.0000000000003048","type":"journal-article","created":{"date-parts":[[2020,5,14]],"date-time":"2020-05-14T02:30:35Z","timestamp":1589423435000},"page":"547-548","source":"Crossref","is-referenced-by-count":1,"title":["Pelvic Leiomyosarcoma With Splenic Metastasis and Response Assessment by 18F-FDG PET\/CT"],"prefix":"10.1097","volume":"45","author":[{"given":"Divya","family":"Yadav","sequence":"first","affiliation":[{"name":"Nuclear Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rakesh","family":"Kumar","sequence":"additional","affiliation":[{"name":"Nuclear Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sameer","family":"Rastogi","sequence":"additional","affiliation":[{"name":"Medical Oncology, IRCH, All India Institute of Medical Sciences, New Delhi, India."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shamim Ahmed","family":"Shamim","sequence":"additional","affiliation":[{"name":"Nuclear Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2020,5,12]]},"reference":[{"key":"bib1-20230925","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.1002\/ijc.22239","article-title":"Incidence patterns of soft tissue sarcomas, regardless of primary site, in the surveillance, epidemiology and end results program, 1978\u20132001: an analysis of 26,758 cases","volume":"119","year":"2006","journal-title":"Int J Cancer"},{"key":"bib2-20230925","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1097\/IGC.0000000000000290","article-title":"Uterine leiomyosarcoma: a review article","volume":"24","year":"2014","journal-title":"Int J Gynecol Cancer"},{"key":"bib3-20230925","doi-asserted-by":"crossref","first-page":"3437","DOI":"10.1002\/cam4.956","article-title":"Survival of patients with metastatic leiomyosarcoma: the MD Anderson Clinical Center for targeted therapy experience","volume":"5","year":"2016","journal-title":"Cancer Med"},{"key":"bib4-20230925","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1097\/PGP.0000000000000284","article-title":"Distant metastases in uterine leiomyosarcomas: the wide variety of body sites and time intervals to metastatic relapse","volume":"36","year":"2017","journal-title":"Int J Gynecol Pathol"},{"key":"bib5-20230925","doi-asserted-by":"crossref","first-page":"306","DOI":"10.3802\/jgo.2014.25.4.306","article-title":"Metastatic pattern of uterine leiomyosarcoma: retrospective analysis of the predictors and outcome in 113 patients","volume":"25","year":"2014","journal-title":"J Gynecol Oncol"},{"key":"bib6-20230925","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1002\/cncr.2820710440","article-title":"Prognostic factors in early-stage uterine sarcoma. A gynecologic oncology group study","volume":"71","year":"1993","journal-title":"Cancer"},{"key":"bib7-20230925","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1159\/000486419","article-title":"Retrospective analysis of outcome of patients with metastatic leiomyosarcoma in a tertiary referral center","volume":"41","year":"2018","journal-title":"Oncol Res Treat"},{"key":"bib8-20230925","first-page":"348910","article-title":"Outcomes of first-line chemotherapy in patients with advanced or metastatic leiomyosarcoma of uterine and non-uterine origin","volume":"2009","year":"2009","journal-title":"Sarcoma"},{"key":"bib9-20230925","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/S1470-2045(17)30622-8","article-title":"Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial","volume":"18","year":"2017","journal-title":"Lancet Oncol"},{"key":"bib10-20230925","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1016\/S0140-6736(12)60651-5","article-title":"Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"379","year":"2012","journal-title":"Lancet"},{"key":"bib11-20230925","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1200\/JCO.2015.62.4734","article-title":"Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: results of a phase III randomized multicenter clinical trial","volume":"34","year":"2016","journal-title":"J Clin Oncol"},{"key":"bib12-20230925","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1097\/MNM.0b013e32832bcaec","article-title":"Fluorodeoxyglucose positron emission tomography in leiomyosarcoma: imaging characteristics","volume":"30","year":"2009","journal-title":"Nucl Med Commun"},{"key":"bib13-20230925","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1159\/000355224","article-title":"Trabectedin in advanced high-grade uterine Leiomyosarcoma: a case report illustrating the value of (18)FDG-PET-CT in assessing treatment response","volume":"7","year":"2014","journal-title":"Case Rep Oncol"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000003048","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T06:10:00Z","timestamp":1695622200000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000003048"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,12]]},"references-count":13,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000003048","relation":{},"ISSN":["1536-0229","0363-9762"],"issn-type":[{"value":"1536-0229","type":"electronic"},{"value":"0363-9762","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5,12]]}}}